GWN Securities Inc. Acquires Shares of 13,127 TG Therapeutics, Inc. (NASDAQ:TGTX)

GWN Securities Inc. acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 13,127 shares of the biopharmaceutical company’s stock, valued at approximately $395,000.

Other institutional investors have also bought and sold shares of the company. State Street Corp lifted its holdings in shares of TG Therapeutics by 35.8% in the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after acquiring an additional 2,398,015 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of TG Therapeutics by 1,549.4% in the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after acquiring an additional 725,371 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of TG Therapeutics in the 4th quarter worth about $14,508,000. Braun Stacey Associates Inc. bought a new stake in shares of TG Therapeutics in the 4th quarter worth about $13,328,000. Finally, Castellan Group bought a new stake in shares of TG Therapeutics in the 4th quarter worth about $8,539,000. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Trading Up 10.2 %

TGTX stock opened at $40.84 on Monday. The company has a market capitalization of $6.41 billion, a PE ratio of -408.36 and a beta of 2.30. TG Therapeutics, Inc. has a 12 month low of $12.93 and a 12 month high of $41.85. The firm’s 50-day moving average is $31.86 and its 200 day moving average is $29.08. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. The business had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. On average, research analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analysts Set New Price Targets

TGTX has been the subject of several analyst reports. JPMorgan Chase & Co. raised their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. Finally, HC Wainwright restated a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $40.67.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 11,337 shares of the firm’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $30.29, for a total transaction of $343,397.73. Following the transaction, the chief financial officer now owns 670,632 shares of the company’s stock, valued at approximately $20,313,443.28. This trade represents a 1.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 10.50% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.